Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 23177515

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2013 Jan 26
First author
Demetri GD

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6.
    note
    Source null
    related pmid
    23177516
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2013 Jan;10(1):1. doi: 10.1038/nrclinonc.2012.222.
    note
    Source null
    related pmid
    23229184
    relationship
    Comment in

Authors and identifiers

  1. name
    Demetri GD
    type
    Author
  2. name
    Reichardt P
    type
    Author
  3. name
    Kang YK
    type
    Author
  4. name
    Blay JY
    type
    Author
  5. name
    Rutkowski P
    type
    Author
  6. name
    Gelderblom H
    type
    Author
  7. name
    Hohenberger P
    type
    Author
  8. name
    Leahy M
    type
    Author
  9. name
    von Mehren M
    type
    Author
  10. name
    Joensuu H
    type
    Author
  11. name
    Badalamenti G
    type
    Author
  12. name
    Blackstein M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Demetri GD
    type
    Author
  2. name
    Reichardt P
    type
    Author
  3. name
    Kang YK
    type
    Author
  4. name
    Blay JY
    type
    Author
  5. name
    Rutkowski P
    type
    Author
  6. name
    Gelderblom H
    type
    Author
  7. name
    Hohenberger P
    type
    Author
  8. name
    Leahy M
    type
    Author
  9. name
    von Mehren M
    type
    Author
  10. name
    Joensuu H
    type
    Author
  11. name
    Badalamenti G
    type
    Author
  12. name
    Blackstein M
    type
    Author
bibliography ids
  1. nci-bib-c963834259982f67017b98c8
book metadata
content sha256
c9823de1564c3323e07eb899ba18f54dbae4e9b71ec67a18d54f98564ef5198e
document type
citation
dois
  1. 10.1016/S0140-6736(12)61857-1
electronic publication date
display
2012 Nov 22
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:23177515
immutable id
pubmed:23177515@c9823de1564c3323e07eb899ba18f54dbae4e9b71ec67a18d54f98564ef5198e
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9863
name
Lancet (London, England)
nlm unique id
2985213R
pages
295-302
volume
381
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6.
    note
    Source null
    related pmid
    23177516
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2013 Jan;10(1):1. doi: 10.1038/nrclinonc.2012.222.
    note
    Source null
    related pmid
    23229184
    relationship
    Comment in
outcomes validated
false
pmid
23177515
provenance
batch id
99e85dbb34a1a3011c9a
provider
NCBI PubMed ESummary
record sha256
3b131c10742b050848d47ce989687232a897951b0344f5d963f6ae133929e932
response sha256
1f4a46dcee9da36f8f58fe356dce3f44a1b3004f404e9fb0184f4e08aed4acf2
retrieved at
2026-09-09T23:46:52.860383+00:00
publication date
display
2013 Jan 26
precision
day
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23177515/
title
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice